Difference between revisions of "Daratumumab (Darzalex)"
Jump to navigation
Jump to search
m |
|||
| Line 18: | Line 18: | ||
*11/16/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472904.htm Granted accelerated approval] for the treatment of patients with [[Multiple_myeloma,_relapsed/refractory|multiple myeloma who have received at least three prior lines of therapy]] including a [[:Category:Proteasome inhibitors | proteasome inhibitor (PI)]] and an [[:Category:Immunomodulatory drugs (IMiDs) | immunomodulatory agent]] or who are double-refractory to a PI and an immunomodulatory agent.<ref name="insert"></ref> | *11/16/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472904.htm Granted accelerated approval] for the treatment of patients with [[Multiple_myeloma,_relapsed/refractory|multiple myeloma who have received at least three prior lines of therapy]] including a [[:Category:Proteasome inhibitors | proteasome inhibitor (PI)]] and an [[:Category:Immunomodulatory drugs (IMiDs) | immunomodulatory agent]] or who are double-refractory to a PI and an immunomodulatory agent.<ref name="insert"></ref> | ||
*11/21/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm530249.htm Approved] in combination with [[Lenalidomide (Revlimid)|lenalidomide]] and [[Dexamethasone (Decadron)|dexamethasone]], or [[Bortezomib (Velcade)|bortezomib]] and [[Dexamethasone (Decadron)|dexamethasone]], for the treatment of patients with [[Multiple_myeloma,_relapsed/refractory|multiple myeloma who have received at least one prior therapy]]. ''(Label extended to second-line setting)'' | *11/21/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm530249.htm Approved] in combination with [[Lenalidomide (Revlimid)|lenalidomide]] and [[Dexamethasone (Decadron)|dexamethasone]], or [[Bortezomib (Velcade)|bortezomib]] and [[Dexamethasone (Decadron)|dexamethasone]], for the treatment of patients with [[Multiple_myeloma,_relapsed/refractory|multiple myeloma who have received at least one prior therapy]]. ''(Label extended to second-line setting)'' | ||
| − | *6/27/2019: Approved in combination with lenalidomide and dexamethasone for patients with [[Multiple_myeloma,_induction|newly diagnosed multiple myeloma]] who are ineligible for autologous stem cell transplant. ''(Label extended to first-line setting)'' | + | *6/27/2019: Approved in combination with lenalidomide and dexamethasone for patients with [[Multiple_myeloma,_induction|newly diagnosed multiple myeloma]] who are ineligible for autologous stem cell transplant. ''(Label extended to first-line transplant-ineligible setting)'' |
| + | *9/26/2019: Approved for adult patients with [[Multiple_myeloma,_induction|multiple myeloma]] in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT). ''(Label extended to first-line transplant-eligible setting)'' | ||
==Also known as== | ==Also known as== | ||
Revision as of 20:08, 26 September 2019
General information
Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc mediated cross-linking, complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). CD38 is present on the cell surface of multiple myeloma (MM), plasma leukemia, and natural killer (NK) cells.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Daratumumab (Darzalex) package insert[1]
- Daratumumab (Darzalex) patient drug information (Chemocare)[5]
- Daratumumab (Darzalex) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 11/16/2015: Granted accelerated approval for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.[1]
- 11/21/2016: Approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. (Label extended to second-line setting)
- 6/27/2019: Approved in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (Label extended to first-line transplant-ineligible setting)
- 9/26/2019: Approved for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT). (Label extended to first-line transplant-eligible setting)
Also known as
- Code name: JNJ-54767414
- Brand names: Darzalex, HuMax-CD38
References
- ↑ 1.0 1.1 1.2 1.3 Daratumumab (Darzalex) package insert
- ↑ Daratumumab (Darzalex) package insert (locally hosted backup)
- ↑ Daratumumab page at NCI Drug Dictionary
- ↑ Darzalex manufacturer's website
- ↑ Daratumumab (Darzalex) patient drug information (Chemocare)
- ↑ Daratumumab (Darzalex) patient drug information (UpToDate)